What is it about?
The markers of hepatic involvement might be used as predictors for the severity of metabolic anomalities.
Featured Image
Why is it important?
In the study group (obese with metabolic syndrome present) the values were significantly higher than in the control group (obese metabolic syndrome - free) : TGP (U/L) - 44.9 ± 3.1 vs 26.4 ± 1.3, TGO (U/L) - 35.5 ± 2.3 vs 22.7 ± 0.9, GGT (U/L) - 55.1 ± 4.6 vs 25.2 ± 1.5
Perspectives
Obese patients with metabolic syndrome have an additional hepatic problem (versus obese patients without metabolic syndrome), that should be accounted for by all range of specialists involved in metabolic syndrome management (general practitioners, cardiologists, endocrinologists, diabetes and internal medicine specialists).
Gheorghe Serpoi
Read the Original
This page is a summary of: Transminases Are Significantly Increased in Patients with Metabolic Syndrome Compared with Obese Controls, Acta Endocrinologica (Bucharest), January 2005, ACTA Endocrinologica Foundation,
DOI: 10.4183/aeb.2005.19.
You can read the full text:
Resources
Contributors
The following have contributed to this page
